NASDAQ$BMEA
Biomea Fusion Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Biomea Fusion reported its financial results for the first quarter ended March 31, 2025, highlighting a strategic realignment to focus on core programs and extend cash runway.
Biomea Fusion executed a focused realignment of operations in Q1 2025 to concentrate resources on high-value opportunities, extend cash runway, and position the company for long-term success. The company reported a net loss of $29.3 million, an improvement from the $39.1 million loss in the same period last year, and ended the quarter with $36.2 million in cash, cash equivalents, and restricted cash.
- Strategic realignment implemented to prioritize core programs: icovamenib and BMF-650.
- Workforce reduction of approximately 35% and consolidation of facilities to reduce operating expenses and extend cash runway into Q4 2025.
- Net loss improved to $29.3 million in Q1 2025 from $39.1 million in Q1 2024.
- Cash, cash equivalents, and restricted cash totaled $36.2 million, sufficient to fund operations into Q4 2025.
Headline financials
Revenue & EPS history
Biomea Fusion · Revenue · Quarterly
$0
Forward guidance
Biomea Fusion is strategically positioned to deliver meaningful clinical data and drive value across its metabolic pipeline, with icovamenib advancing in insulin-deficient type 2 diabetes patients and BMF-650 on track for IND submission. The company expects its cash runway to extend into the fourth quarter of 2025.
Tailwinds
- Icovamenib progressing toward the next phase of clinical development in insulin-deficient type 2 diabetes patients.
- BMF-650 (next-generation oral GLP-1 receptor agonist) on track for IND submission in H2 2025.
- 52-week data from Phase II COVALENT-111 study in type 2 diabetes expected in H2 2025.
- Type-C meeting planned with FDA in H2 2025 to discuss Phase IIb trial design for icovamenib.
- Preliminary data from Phase II COVALENT-112 study in type 1 diabetes anticipated in H2 2025.
Headwinds
- All other clinical and preclinical activities are either being partnered or closed.
- Workforce reduction of approximately 35% implemented.
- Consolidation of workforce to one facility, eliminating costs of maintaining two separate facilities.
- The Company concludes its oncology efforts with BMF-500 and is exploring strategic partnerships.
- Potential delays in preclinical or clinical development, patient enrollment, and trial completion.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2025
+5.2%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+3.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+109.7%
Q4 2022
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +15.3% | -13.5% | -23.7% | |
| Q3 2025 | -0.7% | -4.3% | -21.0% | |
| Q2 2025 | +0.6% | -3.2% | +21.5% | |
| Q1 2025 | -1.3% | -4.6% | +73.0% | |
| Q4 2024 | +1.2% | -7.8% | -8.7% | |
| Q3 2024 | -16.7% | -27.2% | -43.4% | |
| Q1 2024 | +6.7% | +3.7% | -9.1% | |
| Q4 2023 | -14.4% | -14.8% | -22.6% | |
| Q3 2023 | -6.8% | -7.9% | +16.3% | |
| Q2 2023 | -2.4% | -9.3% | -22.2% | |
| Q1 2023 | -3.3% | +2.6% | +12.5% | |
| Q4 2022 | +109.7% | +101.0% | +84.6% | |
| Q3 2022 | -15.6% | -29.4% | -43.3% | |
| Q2 2022 | +3.3% | +11.8% | +8.5% | |
| Q1 2022 | +35.2% | +69.4% | +127.2% | |
| Q4 2021 | -13.8% | -7.7% | -36.2% | |
| Q3 2021 | +7.6% | +2.0% | -7.9% | |
| Q2 2021 | -0.6% | -11.0% | -3.4% | |
| Q1 2021 | -0.3% | +7.9% | -21.4% | |
| Q4 2020 | -0.3% | +7.9% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro